Preclinical Wound Therapeutics
Preclinical Wound Therapeutics - Related Videos
06:51
A Preclinical Murine Model of Hepatic Metastases
0 Views •
Cited by 119 •
2014
A preclinical, murine model of hepatic metastases performed via a hemispleen injection technique.
05:39
Murine Model of Wound Healing
0 Views •
Cited by 207 •
2013
A murine model of cutaneous wound healing that can be used to assess therapeutic compounds in physiological and pathophysiological settings.
08:35
Demonstration of the Rat Ischemic Skin Wound Model
0 Views •
Cited by 32 •
2015
The rat, due to its size, availability, and rather docile behavior, has been utilized as a research model for many years. The goal of this protocol is to utilize the rat as an ischemic skin wound healing model to provide valuable insight into the pathophysiology of chronic wounds.
08:29
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
0 Views •
Cited by 12 •
2014
Established cancer cell lines and xenografts have been the mainstay of cancer research for the past several decades. However, recent evidence suggests that therapeutic response is greatly influenced by the tumor cell microenvironment. Therefore, we have developed an ex vivo analysis of primary tumor specimens for drug development purposes.
04:58
Collecting And Measuring Wound Exudate Biochemical Mediators In Surgical Wounds
0 Views •
Cited by 6 •
2012
This article provides a detailed and visual description of a methodology for collecting and measuring biochemical inflammatory and nociceptive mediators at the surgical wound site following cesarean delivery. This human bioassay has been used to determine correlations between wound and serum cytokine concentrations and drug-mediated changes in wound cytokines, chemokines and neuropetides.
FAQs
These processes form a coordinated sequence rather than isolated events. Inflammation helps shape the early response to injury, while cell migration supports movement into the damaged region. Extracellular-matrix deposition provides structural material, angiogenesis supports developing tissue, and remodeling reorganizes that material as repair progresses. Preclinical analysis examines whether a therapy improves coordination across these stages rather than affecting only one event.
Both processes influence whether newly forming tissue can become organized and sustained. Extracellular-matrix deposition contributes to the structural environment of repair, whereas angiogenesis contributes to blood-vessel formation within recovering tissue. A candidate treatment may therefore be evaluated for effects on these mechanisms alongside inflammation and cell migration. Considering several processes helps reveal whether healing potential reflects broader tissue recovery.
Dose and delivery strategy determine how a candidate treatment is presented during preclinical evaluation. Testing these variables helps identify conditions associated with healing potential while also revealing potential adverse effects. The goal is not simply to show that a therapy has activity, but to refine how it is administered so that its influence on repair processes can be assessed consistently before clinical testing.
Controlled wound models allow investigators to compare treatment-related changes using measurable repair outcomes. These outcomes can be interpreted alongside biological processes such as inflammation, cell migration, extracellular-matrix deposition, angiogenesis, and tissue remodeling. Combining process-level observations with overall recovery provides a more informative assessment than relying on a single indicator, helping distinguish limited biological effects from broader improvement in tissue repair.
Evaluation begins with a controlled wound model in which a candidate treatment can be examined under defined conditions. Investigators then assess healing-related biological responses and measurable repair outcomes, while considering dose, delivery strategy, safety, and potential adverse effects. The resulting evidence supports therapeutic refinement and helps determine whether the candidate has sufficient promise for further development before human testing.
These studies are useful when a therapy is being considered for acute, chronic, or otherwise difficult-to-heal wounds. The models help connect molecular mechanisms with whole-tissue recovery and can reveal whether a candidate influences coordinated repair processes. They also provide information for refining treatment conditions and planning clinical trials, making them relevant when standard healing may be inadequate or difficult to predict.